Appendix: Claim Support Table

Claim	Location of support in 60/139,172, filed June 15, 1999 (6420US)
1. (Currently Amended) A protein purified to apparent homogeneity comprising ~~a segment of a β-secretase enzyme protein comprising~~	Page 36, lines 10-14
residues 63-452 of SEQ ID NO:2~~, the segment comprising valine at a position corresponding to position 130 of SEQ ID NO:2~~,	Page 30, lines 1-6
wherein the protein lacks ~~a signal sequence (~~amino acid residues ~~1-21 of SEQ ID NO:2) and the putative pro region (amino acid residues 22-45~~ 1-45 of SEQ ID NO:2)	Page 31, lines 3-6
wherein the protein exhibits β-secretase activity.	Page 21, lines 4-8
15. (Currently Amended) The protein of claim 1, wherein said amino acid sequence of the protein consists of ~~a polypeptide having the amino acid sequence~~ SEQ ID NO: 43.	Page 10, lines 11-16

Claim	Location of support in 60/139,172, filed June 15, 1999 (6420US)
18. (Currently Amended) The protein of claim 1, wherein said protein has an N-terminal residue corresponding to a residue selected from the group consisting of residues 46, 58 and 63 of SEQ ID NO: 2~~with respect to SEQ ID NO: 2~~ and a C-terminus selected from a residue between positions 452 and 501 of SEQ ID NO:2~~with respect to SEQ ID NO: 2~~.	Page 29, line 24 to page 30, line 6
22. (Previously Presented) The protein of claim 1, wherein said protein is produced by a heterologous cell.	Page 13, lines 29-30, page 14, lines 1-4, and page 36, lines 25-26
23. (Previously Presented) A crystalline protein composition formed from the protein of claim 1.	Page 31, lines 3-12
24. (Previously Presented) The crystalline protein composition of claim 23,	Page 31, lines 3-12
wherein said purified protein is characterized by a binding affinity for the β-secretase inhibitor substrate P10-P4'sta D→V which is at least 1/100 of an affinity exhibited by a protein	Page 31, lines 13-29
having the amino acid sequence SEQ ID NO: 43, when said proteins are tested for binding to said substrate under the same conditions.	Page 29, lines 24-26

25. (Previously Presented) The crystalline protein composition of claim 23,	Page 31, lines 3-12
wherein said composition is formed from a protein having a sequence selected from the group consisting of SEQ ID NO: 43,	Page 29, lines 24-26
and SEQ ID NO: 71.	Page 31, lines 23-27
29. (Original) The crystalline protein composition of claim 23, wherein said protein is glycosylated.	Page 32, lines 7-13
30. (Original) The crystalline protein composition of claim 23, wherein said protein is deglycosylated.	Page 32, lines 7-13
31. (Original) The crystalline protein composition of claim 23, wherein said composition further includes a β-secretase substrate or inhibitor molecule.	Page 33, lines 21-23 and page 35, lines15-25
33. (Original) The crystalline protein composition of claim 31, wherein said β-secretase inhibitor ~~has~~ consists of the sequence SEQ ID NO: 72 [P10-P4'sta D→V], ~~including conservative substitutions thereof~~.	Page 35, lines 26-28

34. (Original) The crystalline protein composition of claim 31, wherein said β-secretase inhibitor ~~has~~ consists of the sequence SEQ ID NO: 81 [EVMXVAEF], wherein X is hydroxyethylene	Claim 19 as filed
or statine.	Claim 17 as filed
36. (Original) The crystalline protein composition of claim 31, wherein said β-secretase inhibitor is characterized by a K_i of no more than about 50 μM.	Claim 21 as filed
132. (Previously Presented) The protein of claim 1, wherein the protein has been purified sufficiently to run as a single band on a SDS PAGE gel under reducing conditions.	Page 23, lines 5-7
133. (Previously Presented) The protein of claim 1, wherein the protein has been purified sufficiently to provide a suitable substrate for N-terminal amino acid determination.	Page 24, lines 2-5
134. (New) The protein of claim 1, wherein the protein comprises SEQ ID NO: 58.	Claim 24 as filed & page 8, line 11